Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00338923
Recruitment Status : Completed
First Posted : June 20, 2006
Last Update Posted : August 17, 2007
Sponsor:
Information provided by:
HealOr

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is a multicenter pilot study to assess the healing effects of HO/03/03 on diabetic neuropathic plantar and venous ulcers.

HO/03/03 action mechanism involves the manipulation of keratinocyte and fibroblast migration and differentiation at the wound area.

  • The primary end point of this study is assessment of safety in treating with HO/03/03 and the efficacy of the drug to promote wound closure of chronic wounds.
  • The secondary end points are assessment time to closure and healing rate for the measurement of wound healing progression.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Venous Ulcer Drug: HO/03/03 Phase 1

Detailed Description:

This is a multicenter pilot study to assess the healing effects of HO/03/03 on diabetic neuropathic plantar and venous ulcers.

Pretreatment phase: During a pretreatment phase that will last up to 14 days, all patients will receive the conventional treatment once a day at the discretion of the investigator. All wounds will be morphologically monitored by photo documentation daily and measurements of wound area once a week.

Initial study visit: patients will begin treatment after completing all necessary demands in pre-treatment phase or after ruling out of all exclusion criteria. All wounds will be cleaned from previous treatment by surgical debridement and irrigation (saline).

Treatment phase: Following the pre-treatment phase, wounds will be treated topically with HO/03/03 for 30 days. During this 30 day phase, patients will receive daily treatments with HO/03/03 either at home by a certified nurse or at the clinic. Wounds will be monitored by certified medical staff member as well as photo documentation. Then application of the treatment followed by a 15-minute rest. Finally wound will be dressed with a fresh dressing and monitoring of any adverse events.

Patients will be administered HO/03/03 in addition to weight off-load Once a week wounds will be monitored by a physician: wounds size will be determined and documented. Patients will be evaluated for pain sensation at the wound area by filling a pain scoring questionnaire.

Twice during the experiment patients will undergo blood profile, HbA1c, blood glucose, and urine samples testing at the initial and terminating visits.

At the conclusion of the treatment phase the following will be completed:

  • A physical examination;
  • Collection of all blood and urine samples for clinical laboratory tests (dip sticks);
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.
Study Start Date : June 2006
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Treatment arm
One Arm - Active Compound (HO/03/03)
 Drug: HO/03/03


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety [ Time Frame: Treatment Period ]

Secondary Outcome Measures :
  1. Time to Heal & Rate of Healing [ Time Frame: Treatment Period ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must satisfy all of the following inclusion criteria to be included in the study:

  1. be male or female over the age of 18;
  2. have a diabetic neuropathic plantar and/or venous ulcer;
  3. wound diameter <10cm;
  4. wound depth is no more than exposed muscle;
  5. have a current physical examination, which reveals no clinically significant abnormalities, except diabetes or diabetic ulcer/wound related condition
  6. be available for the entire study period, and be able and willing to adhere to protocol requirements;
  7. vascular inflow as measured by Doppler: ABI >= 0.7
  8. have a debilitating wound over a period of 1 month prior to the experiment;
  9. if female of childbearing potential, must be using a reliable form of birth control;
  10. provide written informed consent prior to admission into the study.

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following exclusion criteria:

  1. have a body mass index (BMI) > 45;
  2. have a glycosylated hemoglobin (HbAlc) > 12.0%;
  3. have a history or presence of HIV or a clinically significant cardiac, gastrointestinal, endocrine, neurological, liver, or kidney disease;
  4. have any clinically significant illness during the 4 weeks prior to admission into the study, except diabetes type1 or type2;
  5. patients on concomitant medications that alter blood glucose levels (e.g., ACE inhibitors, lipid lowering agents, etc) must be on a stable dosage regimen for at least 4 weeks prior to entry into the study and the dosage must remain stable throughout the study;
  6. patients on chemotherapy;
  7. participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study;
  8. are pregnant or lactating;
  9. visible bone exposure at wound site;
  10. have any signs of clinical infection in the wound (which could be linked to raised body temperature), necrosis, erythema or mild drainage;
  11. have any acute illness within 2 weeks prior to Screening;
  12. residing in a nursing facility and/or are bed-ridden (unable to come to receive treatment at the clinic);
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00338923


Locations
Layout table for location information
Israel
Assaf Harofe Medical Center
Beer Yaakov, Israel, 70300
Hadassah Ein Kerem Medical Center
Jerusalem, Israel
Kaplan Medical Center
Rechovot, Israel
Sponsors and Collaborators
HealOr
Investigators
Layout table for investigator information
Principal Investigator: Micha Rapoport, Dr. Assaf Harofe Medical Center
Principal Investigator: Leon Gilead, Dr. Hadassah Ein Kerem Medical Center
Principal Investigator: Zvi Landau, Dr. Kaplan Medical Center
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00338923    
Other Study ID Numbers: HO-01-05
First Posted: June 20, 2006    Key Record Dates
Last Update Posted: August 17, 2007
Last Verified: August 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Varicose Ulcer
Foot Ulcer
Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
 Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases
Varicose Veins